Tbg Diagnostics Limited (TDL:ASX)

27.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $58.74M
Last trade 07.10am 21/01/2021 20mins delayed

Latest Announcements

20/11/2020TDLTbg Diagnostics Limited
11/11/2020 Price SensitivePSTDLTbg Diagnostics Limited
02/11/2020 Price SensitivePSTDLTbg Diagnostics Limited
02/11/2020 Price SensitivePSTDLTbg Diagnostics Limited
21/09/2020 Price SensitivePSTDLTbg Diagnostics Limited
02/09/2020 Price SensitivePSTDLTbg Diagnostics Limited
31/08/2020 Price SensitivePSTDLTbg Diagnostics Limited
31/07/2020 Price SensitivePSTDLTbg Diagnostics Limited

Company Overview

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

TDL in the news

Search Previous Announcements